Cambridge Healthtech Institute’s inaugural conference on Use of CRISPR & RNAi for Drug Discovery will cover the latest in the use of CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas9-based gene editing and RNA interference (RNAi) for use in drug discovery and for developing novel drug therapies. It will bring together experts from all aspects of basic science and clinical research to talk about how and where gene editing and RNAi can be best applied. The talks will discuss how the CRISPR/Cas system compares to RNAi and if they can be used in a complementary fashion. Scientists and clinicians will share best practices on everything from assay design to data analysis when conducting low and high throughput screens and generating cellular models, both in vitro and in vivo, using CRISPR/Cas9, siRNA (small interfering RNA), and shRNA (short hairpin RNA) for functional screening, pathway analysis, target discovery, disease modeling, and for enabling cell and viral therapies.